The boomerang boy impacting gene therapies

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:
Growing a CDMO while dealmaking in a gene therapy company…at the same time
Selling a revenue-generating therapy company to Bayer during the pandemic
Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 

Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 
Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.